Buscar:
Resultado de la búsqueda: 653 ensayos clínicos: (433 ensayos de REEC + 220 ensayos de EudraCT)
Mostrar: Resultados
 N. EudraCT..   Ensayos   Patología   Fases   Reclutamiento   Centros   Fármacos   Fuente   Pdf / Link 
2011-002184-17A two part, double-blind, randomized, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric patients with previously treated chronic immune (idiopa... TrombopeniaFASE IIIPor DeterminarEltrombopag, Eltrombopag ELTROMBOPAG SB-497115 Powder for oral suspension, ELTROMBOPAG SB-497115 Film-coated tabletEudraCTLink
2011-001354-29An open-label, multicentre efficacy and safety study of I10E in patients with primary Immune ThrombocytoPenia (ITP) Estudio multicéntrico, abierto, de eficacia y seguridad de I10E en pacientes con trombocitopenia inmune primaria (TPI)TrombopeniaFASE IIIPor DeterminarHUMAN NORMAL IMMUNOGLOBULIN FOR INTRVENOUS USE I10E Solution for infusionEudraCTLink
2010-019987-35Estudio de fase 2, intervencionista, de un solo brazo para describir la respuesta plaquetaria y las tasas de remisión de PTI en sujetos adultos con Púrpura Trombocitopénica Inmune que reciben Romiplostim.-------------------------------------------... TrombopeniaFase IIPor DeterminarNPLATE 500 microgramos polvo para solución inyecta Powder for solution for injectionEudraCTLink
2008-004347-10A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in BoneMarrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment ofThrombocytopenia Associated with Immune (Idiopathic) Thrombocytopenia Purpura (ITP).------... TrombopeniaFase IVPor DeterminarNplate Romiplostim AMG 531 Powder for solution for injectionEudraCTLink
2008-000660-17TPL108392: ?Estudio abierto, multicéntrico y con cambio de grupo para evaluar la seguridad y la eficacia de eltrombopag en sujetos trombocitopénicos con infección por el virus de la hepatitis C (VHC) que por lo demás son elegibles para iniciar t... TrombopeniaFASE IIIPor DeterminarEltrombopag, Eltrombopag SB-497115 Film-coated tablet, Ribavirin, Ribavirin Eltrombopag SB-497115 Film-coated tabletEudraCTLink
2007-006081-15A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, non-splenectomized adult subjects."Estudio abierto, mu... TrombopeniaFase IIPor Determinarsym001 Solution for injectionEudraCTLink
2007-005851-40Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico para evaluar la seguridad y eficacia de Eltrombopag para reducir la necesidad de transfusión de plaquetas en sujetos trombocitopénicos con enfermedad hepática crónica que ... TrombopeniaFASE IIIPor DeterminarEltrombopag, Eltrombopag Eltrombopag SB-497115 Film-coated tabletEudraCTLink
2007-003569-42Estudio Aleatorizado, Doble Ciego, Controlado con Placebo, de Fase 1/2 para Determinar la Seguridad y la Eficacia de AMG 531 en Sujetos Pediátricos Trombocitopénicos con Púrpura Trombocitopénica Inmune (Idiopática) CrónicaTrombopeniaFase IIPor DeterminarAMG 714, AMG 714 proteína recombinante estimulante de la megacariop AMG 531 Powder for solution for injectionEudraCTLink
2006-002946-13A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoietin receptor agonist, in previously treated pediatri... TrombopeniaFase IIPor DeterminarEltrombopag, Eltrombopag Eltrombopag SB-497115 Film-coated tablet, Eltrombopag SB-497115 Film-coated tabletEudraCTLink
2006-002943-10REPEAT. Repeated ExPosure To Eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura. An Open-label repeat dosing study of eltrombopag olamine (SB-497115-GR) in adult subjects, with chronic idiopathic thrombocytopenic purpura (ITP)TrombopeniaFase IIPor DeterminarEltrombopag, Eltrombopag Eltrombopag SB497115 Tablet, Eltrombopag SB497115 TabletEudraCTLink
2006-000470-78A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult ... TrombopeniaFASE IIIPor DeterminarEltrombopag, Eltrombopag Eltrombopag SB497115 Tablet, Eltrombopag SB497115 TabletEudraCTLink
2004-000368-28A Double-blind, Randomised, Multicentre, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (SB-497115-GR) Administered at 50, 75, and 100 mg to Cance... TrombopeniaFase IIPor DeterminarSB497115 SB497115 TabletEudraCTLink
2004-000367-98A double-blind, randomised, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor agonist, administered at 30, 50 and 75 mg as oral... TrombopeniaFase IIPor DeterminarSB497115 TabletEudraCTLink